Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Zhang

OA13.06 Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes With Radiation Dosimetric and Pathologic Analyses

Journal of Thoracic Oncology

English

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology

English

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Journal of Thoracic Oncology

English

OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

Journal of Thoracic Oncology

English

P1.01-110 Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated With Afatinib

Journal of Thoracic Oncology

English

P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study

Journal of Thoracic Oncology

English

P1.04-05 Elucidating the Role of Leukocyte-Associated Immunoglobin-Like Receptor 2 (LAIR2) in Lung Cancer Development

Journal of Thoracic Oncology

English

MA02.05 a Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC

Journal of Thoracic Oncology

English

P053 the Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel

Journal of Thoracic Oncology

English

P101 Intratumor Heterogeneity Comparison Among Different Subtypes of NSCLC Through Multi-Region Tissue and ctDNA Sequencing

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Zhang

OA13.06 Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes With Radiation Dosimetric and Pathologic Analyses

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

P1.01-110 Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated With Afatinib

P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study

P1.04-05 Elucidating the Role of Leukocyte-Associated Immunoglobin-Like Receptor 2 (LAIR2) in Lung Cancer Development

MA02.05 a Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC

P053 the Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel

P101 Intratumor Heterogeneity Comparison Among Different Subtypes of NSCLC Through Multi-Region Tissue and ctDNA Sequencing